MedTrace Logo

Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases

NCT02059538 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2350

Last updated 2014-08-29

No results posted yet for this study

Summary

Supported by state-of-the-art systems medicine competences including integrative computational and functional genomics, the overarching goal of the trial is to investigate the impact of qualitative and quantitative changes in the gut microbiota on the pathogenesis of cardiometabolic diseases (CMDs) and their associated co-morbidities. A major objective will be to translate the clinical and fundamental based discoveries into new diagnosis and preventive actions paving the way to novel modes of treatment in the successive stages of CMD progression.

Conditions

Interventions

OTHER

Adipose tissue biopsies (omental and subcutaneous) liver

RADIATION

CT-scan

OTHER

Stools sampling

OTHER

DNA sampling

OTHER

Blood sampling

OTHER

Urine sampling

RADIATION

Dual energy X-ray absorptiometry-scan (DEXA-scan)

Sponsors & Collaborators

  • European Union

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Karine Clement, Professor · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-06-30
Completion
2016-06-30

Countries

  • Denmark
  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059538 on ClinicalTrials.gov